Emmessar Biotech & Nutrition Ltd (EMMESSA) — shareholding pattern, promoter holding, financials and share price
About Emmessar Biotech & Nutrition Ltd (EMMESSA)
Emmessar Biotech & Nutrition Ltd operates in the Commodity Chemicals industry, within the Chemicals sector. It trades on the NSE as EMMESSA and on the BSE under scrip code 524768. Its ISIN is INE634B01016.
Incorporated in 1992, Emmessar Biotech & Nutrition Ltd is in the business of Healthcare, Fine Chemicals and Renting of Immovable property [1]
Emmessar Biotech & Nutrition Limited, originally Emmessar Chemical Industries Ltd, specializes in manufacturing specialty fine chemicals and biotech solutions.
The company transitioned into healthcare and biotechnology after realizing their chemicals' potential as 'Vital Micro Nutrients', significantly expanding its business scope.
Listed peers in Commodity Chemicals: Omkar Pharmachem Ltd, Sreechem Resins Ltd, Link Pharma Chem Ltd, Kuwer Industries Ltd, Lime Chemicals Ltd, Bhagawati Oxygen Ltd.
Valuation & Returns
10 Jul 2026At ₹24.62 a share on 10 Jul 2026, Emmessar Biotech & Nutrition Ltd (EMMESSA) was valued at a price-to-earnings ratio of 28.59x against an industry P/E of 45.11x and a price-to-book of 1.66x on a book value of ₹14.82 per share as of Mar 2024. Solomo computes return on equity of 5.81% and return on capital employed of 7.72% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 28.59x
- Industry P/E
- 45.11x
- P/B
- 1.66x
- EPS (TTM)
- ₹0.86
- Book value / share
- ₹14.82
- ROE
- 5.81%
- ROCE
- 7.72%
- ROA
- 4.92%
- Debt / equity
- 0.01x
- Dividend yield
- 0%
- EBITDA margin
- 191.67%
- 52-week range
- ₹18.42 – ₹42.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Emmessar Biotech & Nutrition Ltd (EMMESSA) reported revenue of ₹0.37 crore, net profit of ₹0.44 crore and earnings per share of ₹0.88. That compares with revenue of ₹0.61 crore and net profit of ₹0.32 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹0.09 crore and net profit ₹0.03 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.36 | 1.02 | 0.56 | 0.61 | 0.37 |
| Net profit (₹ cr) | 0.48 | 0.5 | 0.75 | 0.32 | 0.44 |
| EPS (₹) | 0.96 | 1 | 1.5 | 0.64 | 0.88 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -14.53% | -2.48% | -57.02% | 8.93% |
| Profit growth | - | 7.06% | -19.74% | -57.33% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 59.53% of Emmessar Biotech & Nutrition Ltd (EMMESSA) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.2%. Market capitalisation was ₹12 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Sandeep Rao 2.04%, HUF 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 59.53% | - | - | 0.2% | 40.47% |
| Mar 2026 | 59.53% | - | - | 0.2% | 40.47% |
| Dec 2025 | 59.53% | - | - | 0.2% | 40.47% |
| Sep 2025 | 59.53% | - | - | 0.2% | 40.47% |
| Jun 2025 | 59.53% | - | - | 0.2% | 40.47% |
| Mar 2025 | 59.53% | - | - | 0.2% | 40.47% |
| Dec 2024 | 59.53% | - | - | 0.2% | 40.47% |
| Sep 2024 | 59.53% | - | - | 0.2% | 40.47% |